Capricor Therapeutics Net Worth
Capricor Therapeutics Net Worth Breakdown | CAPR |
Capricor Therapeutics Net Worth Analysis
Capricor Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Capricor Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Capricor Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Capricor Therapeutics' net worth analysis. One common approach is to calculate Capricor Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Capricor Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Capricor Therapeutics' net worth. This approach calculates the present value of Capricor Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Capricor Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Capricor Therapeutics' net worth. This involves comparing Capricor Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Capricor Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Capricor Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Capricor Therapeutics' net worth research are outlined below:
| Capricor Therapeutics is way too risky over 90 days horizon | |
| Capricor Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 25.18 M. Net Loss for the year was (22.29 M) with profit before overhead, payroll, taxes, and interest of 1.75 M. | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (25.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Capricor Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development DelveInsight |
Capricor Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Capricor Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Capricor Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Capricor Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Capricor Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Capricor Therapeutics backward and forwards among themselves. Capricor Therapeutics' institutional investor refers to the entity that pools money to purchase Capricor Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 158.4 K | Partner Fund Management Lp | 2024-09-30 | 152.8 K | Ghost Tree Capital, Llc | 2024-09-30 | 125 K | Stempoint Capital Lp | 2024-09-30 | 93.6 K | Schonfeld Strategic Advisors Llc | 2024-09-30 | 90.4 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 89.3 K | Boothbay Fund Management, Llc | 2024-09-30 | 87.8 K | Ubs O'connor Llc | 2024-09-30 | 82.9 K | Goldman Sachs Group Inc | 2024-06-30 | 82.7 K | Blackrock Inc | 2024-06-30 | 1.6 M | Vanguard Group Inc | 2024-09-30 | 1.6 M |
Follow Capricor Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 865.75 M.Market Cap |
|
Project Capricor Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.88) | (0.83) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.99) | (0.94) |
When accessing Capricor Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Capricor Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Capricor Therapeutics' profitability and make more informed investment decisions.
Evaluate Capricor Therapeutics' management efficiency
Capricor Therapeutics has return on total asset (ROA) of (0.4449) % which means that it has lost $0.4449 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.9269) %, meaning that it created substantial loss on money invested by shareholders. Capricor Therapeutics' management efficiency ratios could be used to measure how well Capricor Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/28/2024, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to grow to -0.83. At this time, Capricor Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/28/2024, Non Current Assets Total is likely to grow to about 8.3 M, while Other Current Assets are likely to drop slightly above 572 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.84 | 0.80 | |
| Tangible Book Value Per Share | 0.84 | 0.80 | |
| Enterprise Value Over EBITDA | (5.15) | (5.41) | |
| Price Book Value Ratio | 5.79 | 6.08 | |
| Enterprise Value Multiple | (5.15) | (5.41) | |
| Price Fair Value | 5.79 | 6.08 | |
| Enterprise Value | 118.5 M | 124.4 M |
Effective leadership at Capricor Therapeutics drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 33.7211 | Revenue 23.2 M | Quarterly Revenue Growth (0.63) | Revenue Per Share 0.732 | Return On Equity (3.93) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Capricor Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Capricor Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Capricor Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Capricor Therapeutics Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Capricor Therapeutics Earnings per Share Projection vs Actual
Capricor Therapeutics Corporate Management
| Deborah Ascheim | Chief Medical Officer | Profile | |
| Kristi Elliott | Chief Officer | Profile | |
| Xavier Avat | Chief Officer | Profile | |
| MD FACC | Executive Board | Profile | |
| Catherine Kelleher | Consultant | Profile | |
| Eduardo Marbn | CoFounder Board | Profile |
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.